Get 40% Off
Is NVDA a 🟢 buy or 🔴 sell?Unlock Now

Alx Oncology Holdings  (ALXO)

NASDAQ
Currency in USD
Disclaimer
15.85
-0.20(-1.25%)
Closed
After Hours
15.850.00(0.00%)
Day's Range
15.6616.29
52 wk Range
3.9417.42
Prev. Close
16.05
Open
16.13
Day's Range
15.66-16.29
52 wk Range
3.94-17.42
Volume
207,653
Average Vol. (3m)
441,397
1-Year Change
141.62%
Shares Outstanding
49,818,812
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
16.90
Upside +6.62%

People Also Watch

27.81
MIRM
-1.45%
24.64
BCYC
+2.75%
3.30
OPFI
-3.23%
2.990
PWFL
+0.34%
15.88
MLYS
+1.40%
How do you feel today about ALXO?
Vote to see community's results!
or

Alx Oncology Holdings  Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company’s pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.